BRCA1 And BRCA2: Timing Ovarian Risk-Reducing Surgery

0
0

For many people with a pathogenic BRCA1 or BRCA2 variant, risk reducing salpingo oophorectomy—removing both fallopian tubes and ovaries—is the established surgery to reduce tubo-ovarian cancer risk. The timing is not one-size-fits-all: it depends on the gene, family history, plans for having children and the effects of menopause before its usual age.

The decision is worth discussing with a genetics or gynecologic cancer specialist before you reach the age range usually recommended for your gene. Surgery lowers risk but does not eliminate it, and removing the ovaries causes infertility and, if you have not already reached menopause, immediate surgical menopause.

When To Consider Risk Reducing Salpingo Oophorectomy

Common US and Australian guidance places risk-reducing surgery after childbearing, typically at ages 35–40 for BRCA1 and 40–45 for BRCA2. The later window for BRCA2 reflects the tendency for tubo-ovarian cancer risk to rise at older ages than it does for BRCA1. These are guideposts for a discussion, not a deadline that accounts for every person’s circumstances.

Recommendations vary by region and organization. Some US and Australian guidance separates the ages by gene; UK NICE guidance emphasizes discussing benefits and harms without specifying the same precise age range. Other guidance, including that from ACOG and ESMO, has used an age range of 35–40 without the same gene-specific distinction. Ask your specialist which current local guideline applies to you and how it fits your individual risk.

A close relative diagnosed with tubo-ovarian cancer at a young age may prompt an earlier conversation about timing. Family history is one part of risk assessment, alongside your specific variant and personal circumstances. It should inform the discussion, rather than automatically dictate a surgery date.

Fertility And Early Menopause Matter

If you may want to carry a pregnancy using your own eggs, discuss fertility before ovary removal: the operation ends the possibility of using eggs still in the ovaries. A fertility specialist can explain whether preservation options are relevant to your plans and what decisions need to happen before surgery. Having children is not a requirement for talking about risk, but surgery is generally considered after childbearing is complete.

Removing both ovaries before natural menopause brings an abrupt drop in ovarian hormones. This can cause symptoms such as hot flushes, sleep disruption and sexual problems, and may affect bone and cardiovascular health. Hormone replacement therapy (HRT) is often recommended after surgery for people who can take it, and can ease some menopause effects; whether it is suitable and which type to use depends on your health and history. Discuss a menopause-care plan before the operation, rather than treating HRT as an afterthought.

Do not count on ovarian cancer screening as an equivalent alternative to surgery: available screening has not been shown to reduce ovarian cancer deaths in people at high inherited risk. Ask your care team what follow-up is appropriate for your situation, especially if you delay an operation.

What Staged Surgery Can And Cannot Tell You

Salpingectomy with delayed oophorectomy removes the fallopian tubes first and leaves the ovaries in place for a time. The approach aims to delay menopause, based in part on evidence that many high-grade serous cancers begin in the tubes. It is being studied, but has not been shown to prevent cancer as effectively as removing both tubes and ovaries.

In the Dutch TUBA study, a nonrandomized preference study, 577 premenopausal BRCA1 or BRCA2 carriers who had completed childbearing reported better menopause-related quality of life after tube removal than after standard surgery during the first year. The difference was smaller among those who used HRT after ovary removal, but remained. This study measured quality of life, not whether staged surgery prevents cancer as well as the standard operation; it cannot establish equal protection.

Larger trials, including TUBA-WISP II and SOROCk, are designed to test cancer outcomes. TUBA-WISP II’s primary results are expected after long-term follow-up, not in the near term. Until safety is established, staged surgery is not an evidence-backed substitute for standard risk-reducing surgery and is generally appropriate only in a clinical trial where available.

Make The Discussion Specific To You

Before deciding, ask how your BRCA gene, variant and family history affect the timing suggested for you; whether your family is complete; what menopause symptoms and longer-term effects to plan for; and whether HRT is an option. Also ask what cancer risk remains after surgery and what follow-up your specialist recommends. A gynecologic oncologist and genetic counselor can help weigh these factors together. This is a personal, high-stakes decision, so seek individualized clinical advice rather than relying on age ranges alone.